FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 703 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ASCO 2023 roundup: Blood tests, drugs and exercise June 12, 2023 Estimate of the Global Economic Cost of the Most Prevalent Cancers... March 13, 2023 Child Cancer Patient And His Dad Have A Little Fun When... October 3, 2019 Immunotherapy before Surgery Appears Effective for Some with Melanoma October 12, 2022 Load more HOT NEWS Removing senescent immune cells could be the key to preventing some... TMB Consortium Develops a TMB Calibration Tool Atlantic rowing trio smash world record and raise thousands for cancer... Junk food marketing restrictions: so near and yet so far
